Heron Therapeutics Inc. (NASDAQ:HRTX) – Equities researchers at Leerink Swann issued their FY2016 earnings per share (EPS) estimates for Heron Therapeutics in a report issued on Tuesday. Leerink Swann analyst J. Gerberry forecasts that the firm will post earnings per share of ($4.23) for the year. Leerink Swann currently has a “Buy” rating and a $34.00 price target on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($0.89) EPS, Q1 2017 earnings at ($0.75) EPS, Q2 2017 earnings at ($0.77) EPS, Q3 2017 earnings at ($0.58) EPS, Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($2.23) EPS, FY2018 earnings at ($1.12) EPS and FY2020 earnings at $4.48 EPS.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a “buy” rating and issued a $46.00 price target on shares of Heron Therapeutics in a report on Wednesday, July 27th. Brean Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a report on Saturday, August 13th. JMP Securities reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Friday, September 9th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $45.00 price target on shares of Heron Therapeutics in a report on Tuesday, September 6th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $41.63.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Shares of Heron Therapeutics (NASDAQ:HRTX) traded down 5.57% during mid-day trading on Friday, hitting $18.65. 273,855 shares of the stock traded hands. The firm’s 50-day moving average is $16.55 and its 200-day moving average is $18.12. Heron Therapeutics has a 52 week low of $13.95 and a 52 week high of $31.32.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Candriam Luxembourg S.C.A. purchased a new position in Heron Therapeutics during the third quarter valued at approximately $1,034,000. Lombard Odier Asset Management USA Corp purchased a new position in Heron Therapeutics during the third quarter valued at approximately $3,015,000. Baker BROS. Advisors LP purchased a new position in Heron Therapeutics during the third quarter valued at approximately $49,230,000. Highbridge Capital Management LLC purchased a new position in Heron Therapeutics during the third quarter valued at approximately $266,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Heron Therapeutics during the third quarter valued at approximately $363,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.